Jefferies Group LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 Sep 21, 2023	SELL	$35.46 - $54.12 $11.2 Million - $17.1 Million	-316,500 Reduced 95.07%	16,400 $833,000
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $1.16 Million - $1.78 Million	32,800 New	32,800 $1.67 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $10.2 Million - $16.4 Million	-332,900 Closed	0 $0
Q3 2021 Sep 21, 2023	BUY	$31.4 - $69.84 $7.99 Million - $17.8 Million	254,300 Added 323.54%	332,900 $11 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $7.99 Million - $17.8 Million	254,300 Added 323.54%	332,900 $11 Million
Q2 2021 Sep 21, 2023	BUY	$40.9 - $64.9 $3.21 Million - $5.1 Million	78,600 New	78,600 $4.97 Million
Q2 2021 Aug 20, 2021	SELL	$40.9 - $64.9 $318 Million - $505 Million	-7,781,400 Reduced 99.0%	78,600 $4.97 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $321 Million - $510 Million	7,860,000 New	7,860,000 $4.97 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.